Activists

Activist hedge fund Glenview Capital filed a 13D on Bausch Health (BHC) after market hours Monday. The $13.3B fund, managed by Larry Robbins, disclosed a 5.9% stake in the pharmaceutical company. Bausch Health is now Glenview's #3 portfolio position. BHC shares closed at $18.79...

On March 4, Marathon Partners called ELF Beauty "undervalued" in a 13D filing with the SEC. The New York City-based hedge fund disclosed a 5.2% stake, and said in the filing it has "engaged, and plans to continue to engage, with the Issuer’s management and Board of...

In a 13D filed on Jan. 21 targeting Garrison Capital (GARS), corporate activist Joseph Stilwell notes that he has taken an "activist position" in 68 publicly-traded companies since 2000. In his most recent 13D, Stilwell Value, LLC disclosed a 5% stake in Garrison, a...

Legion Partners disclosed a 5.15% stake in Landec Corp (LNDC) after market hours on Thursday. The hedge fund stated it believes LNDC's stock price "does not reflect the Issuer’s intrinsic value." Legion believes that Landec is "engaged in an odd combination of businesses that will never achieve...

Engine Capital filed a 13D on Cymabay (CBAY) two weeks after the development stage biotech company halted a trial of its leading drug candidate causing it's shares to fall as much as 75%. In a 13D filing Thursday evening, New York-based Engine Capital, L.P....

Benjamin Graham activist investor. That's not a term we often hear. Usually Ben Graham is referred to as "The Father of Value Investing." He's the man who coined the term "margin of safety" -- minimizing risk and maximizing profits by buying stocks at deep discounts to intrinsic...

Engine Capital filed a 13D targeting PDL BioPharm (PDLI) on Wednesday morning, disclosing a 5.28% stake in the Nevada-based healthcare stock. Engine also disclosed it sent a letter to PDLI's board saying the fund "invested in PDLI because of the significant intrinsic value attributable to...

Billionaire Mori Arkin filed a 13D on Aclaris Therapeutics (ACRS), a development stage microcap biotech company with a promising treatment for common warts. Arkin bought the shares through his personal partnership, "The 1999 Company." In the activist filing he disclosed the following trades: Purchase/SaleSharesPriceDate Running ...

Cloning Carl Icahn is a good idea. Now I'm of course not talking about a laboratory experiment whereby we create an army of little corporate activists that will grow into so many billionaires. Rather, I'm referring to following the renowned...

Hudson Executive Capital disclosed on Monday that it bought 143,200 shares of USA Technology (USAT) at $4.46 along with call options giving the fund the right to buy another 1,250,000 shares of stock at $10. The call options expire on Jan. 17, 2020.